DEALS AND FINANCING
SOTIO Biotech partners with Merck on IL-15 superagonist combined with Keytruda
SOTIO Biotech has entered into a clinical trial collaboration and supply agreement with Merck & Co. to evaluate combination of SOT101, SOTIO’s IL-15superagonist,with Keytruda in patients with selected advanced/refractory solid tumors in Phase 2 AURELIO-04 study.SOT101 in combination with Keytruda has shown promising clinical efficacy across multiple indications in our ongoing phase 1/1b AURELIO-03 study. SOTIO will conduct a Phase 2 open-label, multicenter study of SOT101 in combination with Keytruda to evaluate efficacy and safety in patients with selected advanced or refractory solid tumors.
The study is expected to treat up to 300 patients with a combination of SOT101 and a standard dose of Keytruda. The study will enroll patients in the US and selected European countries across six different indications, including second line non-small cell lung cancer, first and second line cutaneous squamous cell carcinoma, first line microsatellite instability-high colorectal cancer, second line hepatocellular carcinoma, first line metastatic castration-resistant prostate cancer, and second line ovarian cancer. Merck will supply Keytruda for the study.
Anaveon closes $120 million B round to accelerate its IL-2 agonist development
Anaveon has agreed a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments, Pfizer Ventures and Pontifax. In connection with the Series B financing, Jasper Bos (Forbion), Tim Anderson (Cowen) and Denis Patrick (Pfizer Ventures) will join the Anaveon Board at closing, which is expected before year end.Anaveon is undertaking a Phase 1/2 study to evaluate the safety, dosing and clinical activity of its lead program, ANV419, a powerful and selective IL-2 agonist in patients with solid tumors.
Proceeds from this financing will enable the Company to pursue multiple parallel Phase 2 programs in order to explore the full therapeutic potential of ANV419. In addition, it will allow Anaveon to continue its work in developing follow-on compounds to expand on the success of ANV419 by delivering the IL-2 agonist to tumor fighting cells and thus expand the therapeutic potential into less immunogenic tumors. Additionally, the company is building on its cytokine engineering expertise with preclinical-stage programs harnessing the power of cytokines for therapeutic purposes.